查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1855544

吸入式一氧化氮市場按產品、應用、最終用戶和分銷管道分類－2025-2032年全球預測

Inhaled Nitric Oxide Market by Product, Application, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，吸入式一氧化氮市場規模將達到 13.1361 億美元，複合年成長率為 6.04%。

關鍵市場統計數據
基準年 2024 8.2109億美元
預計年份：2025年 8.7137億美元
預測年份 2032 13.1361億美元
複合年成長率 (%) 6.04%

全面介紹吸入一氧化氮的臨床作用、輸送方式及其在從新生兒到成人的肺部護理中的策略意義。

吸入一氧化氮（iNO）已從一種小眾療法發展成為多種急性慢性肺部疾病的重要輔助治療。一氧化氮作為一種選擇性肺血管擴張劑，在需要快速調節肺血管阻力和氧合的情況下發揮重要作用，這為其臨床效用提供了有力支持。臨床醫生和醫療系統領導者日益將iNO視為在常規治療方法不足時提供標靶呼吸支持的關鍵工具，這引起了醫院管理者、呼吸治療團隊和採購部門的廣泛關注。

隨著新生兒加護治療、成人重症加護和專科肺科計畫之間的診療路徑日益融合，相關人員都在尋求更深入地了解產品形式、輸送平台和分銷管道如何影響臨床工作流程和營運準備。本報告重點在於氣瓶、產生器和罐式氣瓶等不同產品形式的差異，以及這些輸送方式如何與特定應用通訊協定相互作用，涵蓋從新生兒肺動脈高壓到成人急性呼吸窘迫症候群的治療。透過整合臨床、物流和支付方的觀點，本報告著重闡述了產品的臨床原理、實際應用場景以及決策者在將吸入一氧化氮（iNO）納入診療路徑時必須考慮的策略因素。

技術進步、監管調整和供應彈性措施如何重塑吸入一氧化氮的臨床應用和籌資策略

近年來，吸入一氧化氮領域發生了許多變革性變化，重塑了臨床應用和供應鏈動態。輸送技術的進步催生了更緊湊、整合化的發生器和攜帶式解決方案，縮短了床邊設置時間，並擴大了其在門診和居家醫療環境中的適用範圍。與技術進步同步，臨床通訊協定的擴展以及吸入一氧化氮在難治性低氧血症和肺動脈高壓治療中的廣泛應用，促使醫療機構的採購重點轉向可靠的按需供應模式。

監管和報銷趨勢也在影響臨床決策，促使醫療機構重新評估治療流程，並增加對員工培訓和基礎設施的投資。臨床團隊與分銷合作夥伴之間的策略夥伴關係已成為緩解供應不穩定和確保醫療服務連續性的關鍵機制。此外，對互通性和數據整合的日益重視促使製造商將使用情況追蹤功能整合到設備中，以支援品質保證，並促進與支付方和醫療系統就合理使用和通訊協定進行討論。總而言之，這些變化正在形成一個臨床療效、交付靈活性和供應韌性日益相互依存的局面。

評估2025年美國關稅調整對吸入式一氧化氮的營運和採購影響，這些調整促使供應商轉向供應鏈彈性計畫。

美國2025年實施的關稅調整對吸入式一氧化氮產品及相關硬體的採購、定價結構和供應鏈規劃產生了複雜的連鎖反應。進口關稅和關稅調整推高了某些進口零件和成品的成本，迫使製造商和經銷商重新評估其籌資策略和庫存狀況。這種環境加速了關鍵製造流程的近岸外包，並促使企業重新談判供應契約，以應對到岸成本和前置作業時間的變化。

醫院和醫療系統採取的應對措施是加強與分銷合作夥伴的協作，以確保簽訂更長期的供應協議和緊急條款。臨床團隊將供應風險評估納入治療方法選擇的討論中，優先考慮能夠可靠地適應不斷變化的商業環境的設備和產品。同時，採購負責人考慮了氣瓶、發生器和儲槽等方案的總擁有成本，並考慮到庫存持有量、運輸限制和培訓需求。這些策略調整降低了因個別關稅波動而導致的供應中斷風險，提高了醫療服務的連續性，並凸顯了靈活合約、多供應商採購和庫存可視性在維持關鍵吸入一氧化氮療法供應方面的重要性。

基於細分市場的詳細洞察，解釋了產品形態、臨床用途、最終用戶環境和分銷管道如何決定採購和臨床部署選擇。

細分市場分析揭示了產品選擇、臨床應用、終端用戶偏好和通路的關鍵差異，這些差異為產品推廣和營運規劃提供了基礎。按產品類型分類，本文探討了氣瓶、產生器和儲罐，每種產品在儲存、床邊工作流程和維護要求方面都有其獨特的影響。氣瓶支援快速部署和小型醫療機構，發生器可為大型醫療機構提供整合劑量控制，而儲槽則非常適合服務多家醫療機構的集中式給藥模式。按應用領域分類，本文探討了成人肺動脈高壓、急性呼吸窘迫症候群（ARDS）和新生兒肺動脈高壓。成人肺動脈高壓依其不同的診斷路徑、併發症情況和長期管理策略，分為特發性肺動脈高壓和續發性肺動脈高壓。在ARDS領域，本文進一步探討了體外膜氧氣療法）和侵入性機械通氣（ICTV），闡述了吸入一氧化氮（iNO）如何與先進的呼吸輔助性治療相結合。在新生兒肺動脈高壓領域，體外膜氧氣療法）和機械通氣得到了進一步研究，凸顯了新生兒科工作流程和設備相容性的重要性。依最終使用者分類，研究對象包括門診手術中心、居家醫療、醫院和專科診所，每種環境對庫存管理通訊協定、人員配備和供應合約模式的要求各不相同。按分銷管道分類，研究對象透過直接競標、分銷合作夥伴和線上管道進行市場調查，這些管道在預期前置作業時間、合約結構以及產品隨附的技術和臨床支援程度方面存在差異。

綜上所述，這種細分揭示了為什麼產品選擇和籌資策略不能一概而論地適用於所有醫療機構。營運多個加護病房的醫院可能會優先選擇整合監測和服務合約的呼吸機平台，而家庭護理計畫則會傾向於選擇配備清晰培訓和遠端監測支援的緊湊型氣瓶解決方案。分銷偏好也各不相同：對於尋求價格和服務保障的大型綜合醫療服務網路而言，直接競標通常是合適的選擇；分銷合作夥伴能夠提供物流知識和覆蓋區域系統的廣泛產品管道；而在線管道則為小型診所和門診病人項目提供了快速補貨的機會。這些細微差別要求製造商和供應商採取獨特的商業性策略和量身定做的臨床支援模式，以期在醫療保健領域獲得長期應用。

美洲、中東和非洲以及亞太地區臨床基礎設施、採購慣例和法規的差異如何塑造差異化策略

在吸入式一氧化氮領域，臨床應用、供應鏈配置和監管參與的優先事項持續受到區域動態的影響。美洲的醫療保健環境多樣，從大型三級醫療中心到鄉村醫院，不一而足，因此，大型醫院需要可擴展的發生器解決方案，而社區和居家醫療項目則需要可攜式氣瓶。在該地區，支付方結構和醫療服務提供者的採購慣例對合約策略和產品協議中包含的支持力度有顯著影響。

歐洲、中東和非洲複雜的法律規範和供應模式有利於靈活應變的供應策略。在一些國家，集中採購和國家指南支援快速採用和標準化通訊協定，而在其他國家，分散的體系則為分銷合作夥伴提供在地化服務和培訓創造了機會。該全部區域重症加護能力和新生兒基礎設施的差異，要求採用能夠適應不同臨床需求和醫療機構能力的靈活供應模式。

亞太地區的特點是成熟城市中心與新興區域醫院之間存在顯著差異，同時基礎設施投資迅速成長，臨床通訊協定也不斷發展。重症加護能力的提升和新生兒服務的擴展推動了對攜帶式和一體化醫療服務系統的需求。製造商和供應商若能使其產品設計與當地的監管要求、培訓基礎設施和物流實際情況相符，便能更好地支持醫療服務的可及性，同時充分利用三大區域不同的報銷和採購環境。

競爭差異化概述：交付創新、卓越服務和策略性經銷夥伴驅動供應商偏好和採購決策。

該領域的競爭格局反映了技術創新、差異化服務模式和策略通路夥伴關係的綜合作用。領先的供應商正在投資於能夠減少臨床操作摩擦的交付平台，包括更簡便的設定、更清晰的劑量控制以及支援文件記錄和品質保證的整合監測。同時，各公司正透過售後服務模式實現差異化，這些模式包括維護合約、臨床教育計畫和遠端支持，以確保持續運作並遵循最佳實踐通訊協定。

與製造商和分銷合作夥伴的夥伴關係已成為商業策略的基石，有助於擴大地域覆蓋範圍並提供可靠的物流支援。透過提供結構化培訓、實證資料包和靈活的資金籌措方案來吸引臨床相關人員的供應商，正逐漸獲得大型醫院系統和新生兒網路的青睞。儘管輸送系統和專有氣體配方相關的智慧財產權仍然重要，但在採購談判中，臨床支援、供應穩定性和設備易用性的綜合作用正變得越來越關鍵。那些展現出強大服務能力並符合當地監管要求的新興參與企業，可能會顛覆與傳統供應商的關係，尤其是在基礎設施投資加速發展的地區。

建議相關人員可以採取哪些行動來協調產品創新、供應彈性、臨床支援和分銷策略，以加快產品採用並減少部署摩擦。

產業領導者應採取整合策略，同時兼顧臨床、營運和商業層面。首先，應優先投資於能夠簡化臨床工作流程並確保在各種醫療環境中可靠運作的交付平台。其次，應建立健全的供應鏈彈性計劃，包括多元化的採購管道、本地庫存安排以及清晰的緊急應變計畫，以減輕貿易中斷和運輸延誤的影響。

第三，制定一套全面的臨床支援方案，包括教育訓練、實施指導和部署後監測，以向臨床醫生和採購團隊展示其價值。第四，根據最終用戶的特徵調整分銷和合約簽訂方式：為大型系統提供直接競標，建立區域分銷經銷夥伴，並為門診病人和小型醫療機構提供線上補貨選項。最後，儘早與當地監管機構和報銷相關人員接洽，明確准入途徑，並使循證實踐符合支付方的預期。透過結合這些步驟，企業可以減少部署阻力，增強臨床信心，並在多元化的醫療保健環境中鞏固商業性地位。

我們透明的調查方法結合了主要相關人員的訪談和二手臨床及監管資訊，以從臨床和採購領域交叉驗證見解。

本分析的調查方法融合了定性和定量方法，旨在從實證觀點分析臨床實踐、採購趨勢和產品部署。主要研究包括對臨床醫生、呼吸治療師、採購人員和分銷負責人進行結構化訪談，以收集有關設備易用性、供應鏈挑戰和臨床通訊協定整合的一線見解。二級資訊來源包括同行評審的臨床文獻、監管指導文件和已發布的臨床實踐標準，從而將對設備和應用的討論建立在醫學認可的證據基礎之上。

數據綜合重點在於跨資訊來源三角驗證，以檢驗觀察到的趨勢並揭示不同應用情境（包括成人肺動脈高壓、急性呼吸窘迫症候群和新生兒肺動脈高壓）中採用促進因素的差異。細分分析透過將產品形式、應用子類型、最終用戶環境和分銷管道映射到實際使用模式和購買行為來建構。對於證據仍在發展中或區域異質性限制了結果普遍適用性的情況，研究明確指出了其局限性和注意事項。該調查方法優先考慮透明度和可重複性，使讀者能夠追溯結論的來源，並了解臨床和營運實際情況如何影響最終的見解。

結論強調以臨床醫生為中心的設計、供應彈性以及協作部署策略是持續獲得吸入一氧化氮療法的基礎。

吸入一氧化氮（iNO）是多種嚴重呼吸道疾病治療中不可或缺且用途廣泛的輔助療法，其有效應用取決於產品設計、臨床通訊協定和給藥策略與實際醫療環境的契合度。 iNO 的臨床進展和給藥創新正在拓展其應用範圍和方式，而採購和監管動態也日益影響其可用性和運作準備。採用整合技術選擇、臨床醫生培訓和供應保障的整體方法的機構，將更有利於確保患者獲得不間斷的治療，並充分發揮該治療方法的臨床益處。

展望未來，成功將取決於協作模式，將製造商、分銷合作夥伴、臨床團隊和採購部門聚集在一起，共同打造適合各種醫療環境的解決方案。透過專注於易於整合、可驗證的臨床支援和靈活的分銷機制，相關人員可以減少採用障礙，並確保在新生兒、成人和門診護理中實現治療目標。結論強調，協作、韌性和以臨床醫生為中心的設計是持續獲得治療和最佳化患者療效的支柱。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 探討吸入一氧化氮療法治療 COVID-19 誘發的急性呼吸窘迫症候群的臨床試驗取得進展
  • 攜帶式一氧化氮輸送系統的出現，使得肺動脈高壓的家庭管理成為可能。
  • 生技公司與設備製造商建立策略夥伴關係，以提高吸入一氧化氮（iNO）的輸送效率
  • 下一代一氧化氮發生器的監管核准在於降低成本和提高可及性
  • 研究聯合治療抗病毒藥物療法和吸入一氧化氮療法對改善呼吸道預後的作用

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 吸入式一氧化氮市場（依產品分類）

  • 圓柱
  • 發電機
  • 油船

9. 吸入式一氧化氮市場依應用領域分類

  • 成人肺動脈高壓
    • 特發性
    • 次發性
  • ARDS
    • 體外膜氧氣療法
    • 侵入性通氣
  • 新生兒肺動脈高壓
    • 體外膜氧氣療法
    • 機械通氣

10. 吸入式一氧化氮市場（依最終用戶分類）

  • 門診手術中心
  • 居家醫療
  • 醫院
  • 專科診所

11. 吸入式一氧化氮市場依分銷管道分類

  • 直接競標
  • 銷售合作夥伴
  • 線上

12. 各地區吸入式一氧化氮市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

13. 吸入式一氧化氮市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各國吸入式一氧化氮市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Mallinckrodt plc
    • Linde plc
    • Air Liquide SA
    • Air Products and Chemicals, Inc.
    • Messer SE & Co. KGaA
    • Nippon Sanso Holdings Corporation
    • Bellerophon Therapeutics, Inc.
    • GENERON IGS Inc.
Product Code: MRR-2D668742FD36

The Inhaled Nitric Oxide Market is projected to grow by USD 1,313.61 million at a CAGR of 6.04% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 821.09 million
Estimated Year [2025] USD 871.37 million
Forecast Year [2032] USD 1,313.61 million
CAGR (%) 6.04%

A comprehensive introduction to inhaled nitric oxide that frames its clinical role, delivery modalities, and strategic relevance across neonatal and adult pulmonary care settings

Inhaled nitric oxide (iNO) has evolved from a niche therapeutic into a critical adjunctive intervention across several acute and chronic pulmonary conditions. Its role as a selective pulmonary vasodilator with rapid onset and short half-life underpins its clinical utility in environments where rapid modulation of pulmonary vascular resistance and oxygenation are required. Clinicians and health system leaders increasingly view iNO as an essential tool for targeted respiratory support when conventional therapies are insufficient, driving interest from hospital administrators, respiratory therapy teams, and procurement functions alike.

As therapeutic pathways converge between neonatal intensive care, adult critical care, and specialized pulmonary programs, stakeholders are seeking deeper understanding of how product formats, delivery platforms, and distribution channels influence clinical workflows and operational readiness. This report centers on product-level differentiation across cylinder, generator, and tanker formats, and how these delivery modalities interact with application-specific protocols from neonatal pulmonary hypertension to acute respiratory distress management in adults. By integrating clinical, logistical, and payer-facing perspectives, the introduction underscores the product's clinical rationale, real-world deployment scenarios, and the strategic considerations that decision-makers must weigh when incorporating iNO into care pathways.

How technological advances, regulatory adjustments, and supply resilience initiatives are collectively reshaping clinical adoption and procurement strategies for inhaled nitric oxide

Recent years have produced several transformative shifts in the inhaled nitric oxide landscape that are reshaping clinical adoption and supply chain dynamics. Advances in delivery technology have enabled more compact, integrated generators and portable cylinder solutions, reducing bedside set-up times and expanding suitability for ambulatory and homecare contexts. Parallel to technological improvements, expanding clinical protocols and broader acceptance of iNO in refractory hypoxemia and pulmonary hypertension scenarios have shifted institutional procurement priorities toward reliable, on-demand supply models.

Regulatory and reimbursement developments have also influenced clinical decision-making, prompting providers to re-evaluate treatment algorithms and to invest in staff training and infrastructure. Strategic partnerships between clinical teams and distribution partners have emerged as a key mechanism to mitigate supply volatility and ensure continuity of care. In addition, a greater emphasis on interoperability and data integration has encouraged manufacturers to incorporate usage-tracking features into devices, supporting quality assurance and facilitating discussions with payers and health systems about appropriate utilization and protocols. Taken together, these shifts are creating a landscape in which clinical effectiveness, delivery flexibility, and supply resilience are increasingly interdependent.

Assessing the operational and procurement consequences of U.S. tariff changes in 2025 that prompted sourcing shifts and supply chain resilience planning for inhaled nitric oxide

The introduction of tariff changes in the United States in 2025 created a complex ripple effect across procurement, pricing structures, and supply chain planning for inhaled nitric oxide products and associated hardware. Import duties and customs adjustments increased the cost of certain imported components and finished delivery systems, prompting manufacturers and distributors to reassess sourcing strategies and inventory practices. This environment encouraged accelerated nearshoring of key manufacturing steps where feasible, as well as renegotiation of supply agreements to accommodate altered landed costs and lead times.

Hospitals and health systems responded by intensifying collaboration with distribution partners to secure longer-term supply contracts and contingency provisions. Clinical teams incorporated supply risk assessments into therapy selection discussions, prioritizing devices and formats that could be supported reliably under altered trade conditions. At the same time, purchasers considered total cost of ownership across cylinder, generator, and tanker options, factoring in inventory holding, transportation constraints, and training requirements. These strategic adaptations reduced exposure to isolated tariff-driven disruptions and enhanced continuity of care, while highlighting the importance of flexible contracting, multi-supply sourcing, and inventory visibility in maintaining access to critical inhaled nitric oxide therapies.

Detailed segmentation-driven insights explaining how product formats, clinical applications, end-user environments, and distribution channels determine procurement and clinical deployment choices

Segmentation analysis reveals critical distinctions in product choice, clinical application, end-user preferences, and distribution pathways that together inform adoption and operational planning. Based on Product, the market is studied across Cylinder, Generator, and Tanker, and each format brings unique implications for storage, bedside workflow, and maintenance requirements; cylinders support rapid deployment and smaller institutions, generators enable integrated dosing controls suited to high-volume centers, and tankers are optimal for centralized supply models serving multiple facilities. Based on Application, the market is studied across Adult Pulmonary Hypertension, ARDS, and Neonatal Pulmonary Hypertension. The Adult Pulmonary Hypertension segment is further studied across Idiopathic and Secondary, reflecting divergent diagnostic pathways, comorbidity profiles, and long-term management strategies. The ARDS segment is further studied across Extracorporeal Membrane Oxygenation and Invasive Ventilation, illustrating how iNO integrates with advanced respiratory support modalities. The Neonatal Pulmonary Hypertension segment is further studied across Extracorporeal Membrane Oxygenation and Mechanical Ventilation, underscoring the specialized neonatal workflows and device compatibility needs. Based on End User, the market is studied across Ambulatory Surgical Centers, Homecare, Hospitals, and Specialty Clinics, with each setting demanding different inventory protocols, staff competencies, and contractual models for supply. Based on Distribution Channel, the market is studied across Direct Tender, Distribution Partner, and Online, and these channels differ in lead time expectations, contract structure, and the degree of technical and clinical support bundled with the product.

Taken together, segmentation clarifies why product selection and procurement strategies cannot be generalized across all care settings. A hospital operating multiple intensive care units will prioritize generator platforms with integrated monitoring and service agreements, whereas homecare programs will prefer compact cylinder solutions with clear training and telemonitoring support. Distribution preferences also vary: direct tenders often suit large integrated delivery networks seeking price and service guarantees, distribution partners provide logistics expertise and breadth of product access for regional systems, and online channels create opportunities for rapid replenishment for smaller clinics and outpatient programs. These nuances demand distinct commercial approaches and tailored clinical support models for manufacturers and suppliers seeking durable adoption across the care continuum.

How regional clinical infrastructure, procurement practices, and regulatory diversity shape differentiated strategies across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics continue to shape priorities for clinical adoption, supply chain configuration, and regulatory engagement within the inhaled nitric oxide landscape. The Americas feature a diverse set of care settings ranging from large tertiary centers to rural hospitals, prompting a dual emphasis on scalable generator solutions for high-volume hospitals and portable cylinder options for community and homecare programs. In this region, payer structures and institutional procurement practices strongly influence contracting strategies and the degree of support bundled with product agreements.

Europe, Middle East & Africa present a complex tapestry of regulatory frameworks and delivery models that favor adaptable supply strategies. In some countries centralized procurement and national guidelines drive rapid uptake and standardized protocols, while in others fragmented systems create opportunity for distribution partners to deliver localized service and training. Differences in critical care capacity and neonatal care infrastructure across this combined region necessitate flexible delivery formats that can be adapted to varied clinical needs and facility capabilities.

Asia-Pacific remains a region of rapid infrastructure investment and evolving clinical protocols, with significant heterogeneity between mature urban centers and emerging regional hospitals. Growing critical care capacity and expanding neonatal services are increasing demand for both portable and integrated delivery systems. Manufacturers and suppliers that align product design with local regulatory requirements, training infrastructure, and logistical realities are positioned to support improved access while navigating diverse reimbursement and procurement environments across the three major regions.

An overview of competitive differentiation where delivery innovation, service excellence, and strategic distribution partnerships drive supplier preference and procurement decisions

Competitive dynamics in this sector reflect a combination of technological innovation, service model differentiation, and strategic channel partnerships. Leading providers are investing in delivery platforms that reduce clinical friction-simpler setup, clearer dosing controls, and integrated monitoring that supports documentation and quality assurance. At the same time, companies are differentiating through after-sales service models that include maintenance contracts, clinical education programs, and remote support to ensure continuous operation and adherence to best-practice protocols.

Partnerships between manufacturers and distribution partners have become a cornerstone of commercial strategy, enabling broader geographic reach and more reliable logistics support. Suppliers that align with clinical stakeholders by offering structured training, evidence packages, and adaptable financing options gain preferred status with major hospital systems and neonatal networks. Intellectual property around delivery systems and proprietary gas formulations remains important, but the combination of clinical support, supply resilience, and device usability is increasingly decisive in procurement discussions. New entrants that demonstrate strong service capabilities and compliance with regional regulatory requirements can disrupt traditional supplier relationships, particularly in regions where infrastructure investment is accelerating.

Actionable recommendations for stakeholders to align product innovation, supply resilience, clinical support, and distribution strategies to accelerate adoption and reduce deployment friction

Industry leaders should pursue an integrated strategy that addresses clinical, operational, and commercial dimensions simultaneously. First, prioritize investment in delivery platforms that simplify clinical workflows and enable reliable performance across diverse care settings; ease of use and interoperability with monitoring systems reduce training burdens and lower the threshold for broader adoption. Second, establish robust supply resilience plans, including diversified sourcing, local stocking agreements, and clear contingency protocols to mitigate the impact of trade disruptions and transportation delays.

Third, develop comprehensive clinical support packages that include education, implementation guidance, and post-deployment monitoring to demonstrate value to clinicians and procurement teams. Fourth, tailor distribution and contracting approaches to end-user profiles: direct tenders for large systems, distribution partnerships for regional coverage, and online replenishment options for outpatient and smaller facilities. Finally, engage with regional regulatory and reimbursement stakeholders early to clarify access pathways and to align evidence generation with payer expectations. These steps, taken together, help organizations reduce deployment friction, increase clinical confidence, and strengthen commercial positioning across heterogeneous healthcare environments.

A transparent methodology combining primary stakeholder interviews and secondary clinical and regulatory sources to triangulate insights across clinical and procurement domains

The research methodology underpinning this analysis integrated qualitative and quantitative approaches to produce an evidence-informed perspective on clinical practice, procurement trends, and product deployment. Primary research involved structured interviews with clinicians, respiratory therapists, procurement officers, and distribution executives to capture frontline insights into device usability, supply chain challenges, and clinical protocol integration. Secondary sources included peer-reviewed clinical literature, regulatory guidance documents, and published clinical practice standards to ground device and application discussions in accepted medical evidence.

Data synthesis emphasized triangulation across sources to validate observed trends and to illuminate differences in adoption drivers across applications such as adult pulmonary hypertension, ARDS, and neonatal pulmonary hypertension. Segmentation analysis was constructed by mapping product formats, application subtypes, end-user environments, and distribution channels to real-world usage patterns and procurement behaviors. Limitations and caveats were explicitly noted where evidence was evolving or where regional heterogeneity constrained generalization. The methodology prioritizes transparency and reproducibility so that readers can trace conclusions back to source inputs and understand how clinical and operational realities informed final insights.

Conclusions emphasizing clinician-centered design, supply resilience, and collaborative deployment strategies as the foundation for sustained access to inhaled nitric oxide therapies

Inhaled nitric oxide remains an essential and versatile adjunct in the management of several severe respiratory conditions, and its effective deployment depends on aligning product design, clinical protocols, and supply strategies with the realities of care environments. Clinical advances and delivery innovation are expanding where and how iNO can be used, while procurement and regulatory dynamics increasingly shape accessibility and operational readiness. Organizations that adopt a holistic approach-one that integrates technology selection, clinician training, and supply resilience-are better positioned to maintain uninterrupted patient access and to realize the full clinical benefit of this therapy.

Looking ahead, success will hinge on collaborative models that bring together manufacturers, distribution partners, clinical teams, and procurement functions to create tailored solutions for each care setting. By focusing on ease of integration, demonstrable clinical support, and adaptable distribution mechanisms, stakeholders can reduce barriers to adoption and ensure that therapeutic objectives are met across neonatal, adult, and ambulatory care contexts. The conclusions emphasize alignment, resilience, and clinician-centered design as the pillars of sustained access and optimized patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Clinical trial advances exploring inhaled nitric oxide therapy for COVID-19 induced acute respiratory distress syndrome
  • 5.2. Emergence of portable nitric oxide delivery systems enabling at home pulmonary hypertension management
  • 5.3. Strategic partnerships between biotech firms and device manufacturers to enhance iNO delivery efficiency
  • 5.4. Regulatory approvals for next generation nitric oxide generators focusing on cost reduction and accessibility
  • 5.5. Research into combination therapies coupling inhaled nitric oxide with antiviral agents for enhanced respiratory outcomes

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Inhaled Nitric Oxide Market, by Product

  • 8.1. Cylinder
  • 8.2. Generator
  • 8.3. Tanker

9. Inhaled Nitric Oxide Market, by Application

  • 9.1. Adult Pulmonary Hypertension
    • 9.1.1. Idiopathic
    • 9.1.2. Secondary
  • 9.2. Ards
    • 9.2.1. Extracorporeal Membrane Oxygenation
    • 9.2.2. Invasive Ventilation
  • 9.3. Neonatal Pulmonary Hypertension
    • 9.3.1. Extracorporeal Membrane Oxygenation
    • 9.3.2. Mechanical Ventilation

10. Inhaled Nitric Oxide Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Homecare
  • 10.3. Hospitals
  • 10.4. Specialty Clinics

11. Inhaled Nitric Oxide Market, by Distribution Channel

  • 11.1. Direct Tender
  • 11.2. Distribution Partner
  • 11.3. Online

12. Inhaled Nitric Oxide Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Inhaled Nitric Oxide Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Inhaled Nitric Oxide Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Mallinckrodt plc
    • 15.3.2. Linde plc
    • 15.3.3. Air Liquide S.A.
    • 15.3.4. Air Products and Chemicals, Inc.
    • 15.3.5. Messer SE & Co. KGaA
    • 15.3.6. Nippon Sanso Holdings Corporation
    • 15.3.7. Bellerophon Therapeutics, Inc.
    • 15.3.8. GENERON IGS Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS INHALED NITRIC OXIDE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. INHALED NITRIC OXIDE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. INHALED NITRIC OXIDE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. INHALED NITRIC OXIDE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY CYLINDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY CYLINDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY CYLINDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY CYLINDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY CYLINDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY CYLINDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY GENERATOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY GENERATOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY GENERATOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY GENERATOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY GENERATOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY GENERATOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY TANKER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY TANKER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY TANKER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY TANKER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY TANKER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY TANKER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY IDIOPATHIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY IDIOPATHIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY IDIOPATHIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY IDIOPATHIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY IDIOPATHIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY IDIOPATHIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY SECONDARY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY SECONDARY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY SECONDARY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY SECONDARY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY SECONDARY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY SECONDARY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY INVASIVE VENTILATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY INVASIVE VENTILATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY INVASIVE VENTILATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY INVASIVE VENTILATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY INVASIVE VENTILATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY INVASIVE VENTILATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY MECHANICAL VENTILATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY MECHANICAL VENTILATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY MECHANICAL VENTILATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY MECHANICAL VENTILATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY MECHANICAL VENTILATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY MECHANICAL VENTILATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY HOMECARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY HOMECARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY HOMECARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY HOMECARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY DIRECT TENDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY DIRECT TENDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY DIRECT TENDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY DIRECT TENDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY DIRECT TENDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY DIRECT TENDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION PARTNER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION PARTNER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION PARTNER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION PARTNER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION PARTNER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION PARTNER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ONLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ONLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ONLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ONLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. AMERICAS INHALED NITRIC OXIDE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS INHALED NITRIC OXIDE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 137. AMERICAS INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 141. AMERICAS INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. NORTH AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 154. NORTH AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 156. NORTH AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 170. LATIN AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 172. LATIN AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2018-2024 (USD MILLION)
  • TABLE 176. LATIN AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2025-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 178. LATIN AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. MIDDLE EAST INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 218. MIDDLE EAST INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 220. MIDDLE EAST INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 222. MIDDLE EAST INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2018-2024 (USD MILLION)
  • TABLE 224. MIDDLE EAST INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2025-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 226. MIDDLE EAST INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 228. MIDDLE EAST INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 230. MIDDLE EAST INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 231. AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 234. AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 235. AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 236. AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 237. AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 238. AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 239. AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2018-2024 (USD MILLION)
  • TABLE 240. AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2025-2032 (USD MILLION)
  • TABLE 241. AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 242. AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 243. AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 246. AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2018-2024 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2025-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. ASEAN INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. ASEAN INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. ASEAN INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 268. ASEAN INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 269. ASEAN INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 270. ASEAN INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 271. ASEAN INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 272. ASEAN INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 273. ASEAN INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2018-2024 (USD MILLION)
  • TABLE 274. ASEAN INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2025-2032 (USD MILLION)
  • TABLE 275. ASEAN INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 276. ASEAN INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 277. ASEAN INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. ASEAN INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. ASEAN INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 280. ASEAN INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 281. GCC INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. GCC INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. GCC INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 284. GCC INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 285. GCC INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 286. GCC INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 287. GCC INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 288. GCC INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 289. GCC INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2018-2024 (USD MILLION)
  • TABLE 290. GCC INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2025-2032 (USD MILLION)
  • TABLE 291. GCC INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 292. GCC INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 293. GCC INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 294. GCC INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 295. GCC INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 296. GCC INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPEAN UNION INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPEAN UNION INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPEAN UNION INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPEAN UNION INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPEAN UNION INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPEAN UNION INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPEAN UNION INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPEAN UNION INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPEAN UNION INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPEAN UNION INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPEAN UNION INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPEAN UNION INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPEAN UNION INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 313. BRICS INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 314. BRICS INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 315. BRICS INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 316. BRICS INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 317. BRICS INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 318. BRICS INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 319. BRICS INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 320. BRICS INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 321. BRICS INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2018-2024 (USD MILLION)
  • TABLE 322. BRICS IN